Medical Cannabis for Alzheimer’s: What It May Ease

113 minute read
0
(0)

Short answer · 1 minute read

Medical cannabis is being studied for a few symptoms of Alzheimer’s disease: agitation, broken sleep and a fading appetite. The trials so far are small and their results are mixed. No study shows that cannabis treats Alzheimer’s or slows it in people. Every form of cannabis acts on the brain and can collide with dementia medicines, so whether to try it is a decision to make with a physician who sees the whole medicine list.

Below, trials in people are kept apart from studies that only observed patients and from work done in mice and cell dishes, and each one is labeled. The full review of the evidence starts at what the research shows.

Why families trust this guide

  • Every research figure carries a source you can open in the reference list.
  • Each study is labeled: trial in people, observation, or work in mice and cells.
  • Studies that found no benefit stay on the page and say so.
  • Checked by physicians licensed in the states where we work. Meet them.

When Alzheimer’s changes sleep, appetite and behavior

Families expect the forgetting. They are rarely ready for the rest: a father dressed and waiting by the door at three in the morning, a plate pushed away for the third day running, a gentle wife who now shouts at the bathroom mirror. These changes can begin before memory loss is severe, and for the person living alongside them they are often the hardest part.

The one doing the night shift stops sleeping too. Every fall, every skipped meal and every new suspicion lands on them, often for years.

Nights that don’t end

The disease disturbs the brain’s internal clock. Late-afternoon restlessness, known as sundowning, rolls into nights of pacing, packing bags or waking others, then long daytime naps. Sleeping pills can add next-morning confusion and a fall on the way to the bathroom.

What trials tested for sleep

Meals left untouched

Weight loss in Alzheimer’s has several causes at once. Food tastes different, the person forgets whether they ate, a fork becomes puzzling, and later chewing and swallowing get harder. Steady weight loss is a signal that care needs to change.

What trials tested for appetite

Agitation and hallucinations

Alzheimer’s paranoia (the conviction that someone is stealing or plotting), sudden anger and seeing people who are not there come from the illness, not from character. Every medicine tried for them carries risks in an older brain.

What trials tested for agitation

Good options are scarce. A phase 3 trial gave escitalopram, an antidepressant, to 173 people with Alzheimer’s and agitation, and it did not beat placebo on its main measure (p = 0.28) [1]. That trial had nothing to do with cannabis. It shows why families go looking for something else.

Which situation is yours?

Pick the one closest to you and the guide points you to the parts that answer it.

A parent or partner has Alzheimer’s

Start with what you see day to day and where it sits on the course of the illness. Then look at what helps at home without any medicine, and at what to bring if you book an evaluation together.

Stages and their symptoms · Care at home · Preparing for the appointment

You have early symptoms or mild cognitive impairment

Mild cognitive impairment (MCI) is a measurable change in memory or thinking that does not yet disrupt daily life. A full memory evaluation comes first, because several look-alikes are treatable.

Early signs and the memory evaluation · Check how your answers fit

Your relative lives in a nursing home or memory care

The facility’s written policy and its staff decide what can be kept and given on site, even where a card is legal. Safety rules for frail residents apply twice over.

Rules in a nursing home or memory care · Safety for older adults

Sedatives, sleeping pills or antipsychotics are already prescribed

Here the medicine list matters more than the diagnosis. Sedation adds up, and some combinations are flagged in clinical data.

Interactions with sedatives · Who should not use cannabis

Your state may not list Alzheimer’s

Programs word their lists differently. Some name Alzheimer’s, some cover a related diagnosis, some leave room for the physician’s judgment. A licensed physician checks the records against your state’s current list.

How states list Alzheimer’s · Find your state’s rules

What is Alzheimer’s disease?

Alzheimer’s disease is a brain disease that slowly destroys memory, thinking and, in time, the ability to manage everyday life [2]. Under the microscope it has two signatures. Amyloid, a protein fragment, clumps into plaques between nerve cells. Tau, a protein that normally keeps the inside of nerve cells in shape, twists into tangles within them. As both spread, synapses (the contact points through which nerve cells pass signals) are lost and the cells die, first in the hippocampus, the region that files new memories. That is why someone can forget this morning’s phone call and still sing every word of the song from their wedding.

About 50 million people worldwide live with Alzheimer’s disease, according to a 2026 study [3]. The name comes from Alois Alzheimer, the German psychiatrist who described the plaques and tangles in a patient’s brain in the early twentieth century.

Is Alzheimer’s the same as dementia?

No. Dementia names a loss of memory and thinking severe enough to get in the way of daily life; it describes what is happening, not why. Alzheimer’s is one cause of dementia, the most common one, alongside vascular disease, Lewy body disease and frontotemporal degeneration. Is Alzheimer’s worse than dementia? The question does not quite fit: the course depends on the cause, and Alzheimer’s is one of the causes.

Dementia

What the word covers

A set of symptoms: memory, language, judgment and orientation slipping to the point that a person needs help.

What it tells the family

How much support is needed now, not what is driving the decline.

Alzheimer’s disease

What the word covers

One specific disease, defined by amyloid plaques, tau tangles and the loss of nerve cells.

What it tells the family

The likely course over years, which medicines and trials apply, and what to plan for.

Alzheimer’s ICD-10 code: G30. The subcodes split it into early onset (G30.0), late onset (G30.1), other forms (G30.8) and unspecified (G30.9); the dementia itself is coded separately.

Genes shape the odds, and this research is large. A 2026 consensus meta-analysis pooled 977,514 people and found 91 regions of the genome tied to Alzheimer’s and related dementias, 16 of them new [4].

The same analysis turned those regions into one score per person and asked how well it predicts what doctors later find in the brain. The chart shows the answer for the two hallmarks of the disease.

How much do genes shift the odds?

How to read it: each row compares people at one end of a genetic risk score with people in the middle. The dot is the best estimate; the bar is the range the true value likely sits in. Right of the center line means the brain change was more likely, left means less likely.

Highest genetic score (top tenth)

Advanced tau tangles at death (Braak stage above 5)

About twice the odds: 2.05× (1.47-2.85) [5]

Moderate or severe amyloid plaques

About twice the odds: 1.96× (1.39-2.78) [5]

Lowest genetic score (bottom tenth)

Advanced tau tangles at death (Braak stage above 5)

About half the odds: 0.47× (0.37-0.61) [5]

Moderate or severe amyloid plaques

Less than half the odds: 0.43× (0.33-0.56) [5]

Genes tilt the odds both ways, roughly doubling or halving them, but no genetic score makes Alzheimer’s certain or rules it out [5].

Show as a table
Odds of each brain change at autopsy compared with people in the middle of the genetic score (meta-analysis, 2025)
GroupBrain changeOdds ratio (95% CI)
Top tenthBraak stage above 5 (tau)2.05 (1.47-2.85) [5]
Top tenthModerate or severe amyloid plaques1.96 (1.39-2.78) [5]
Bottom tenthBraak stage above 5 (tau)0.47 (0.37-0.61) [5]
Bottom tenthModerate or severe amyloid plaques0.43 (0.33-0.56) [5]

Quick answers

Is Alzheimer’s hereditary?

Partly. A rare early-onset form runs in families through single genes. The common late-onset form comes from many genes that each nudge the risk, plus age and health over a lifetime. A parent with Alzheimer’s raises your own risk without making it a certainty; the top of the genetic score roughly doubles the odds, it does not guarantee the disease [5].

How is it diagnosed? Criteria, memory tests, scans and blood tests

The doctor takes a history (often with a relative present), runs memory and thinking tests, and orders blood work to rule out look-alikes such as low vitamin B12 or an underactive thyroid. A brain MRI or CT looks for strokes, tumors or fluid build-up. To confirm Alzheimer’s itself, doctors use biomarkers, meaning measurable traces of the disease: amyloid and tau in spinal fluid, PET scans of the brain, and increasingly blood tests for the same proteins [2].

Can Alzheimer’s come on suddenly?

No. Alzheimer’s builds over years. Confusion that appears within hours or days points elsewhere until proven otherwise: a urinary or chest infection, dehydration, pain, constipation or a new medicine can all cause delirium. That deserves a call to a doctor the same day.

Alzheimer’s in men vs women: is there a difference?

More women than men live with Alzheimer’s, partly because women live longer. Biology may play a part too. In one study of older adults without dementia, links between the body’s own cannabinoids in the blood and thinking scores showed up mainly in women [6], and a cost study found cognitive impairment added about $6,883 a year in health costs for women and $7,276 for men [7].

Can children get Alzheimer’s?

Alzheimer’s disease does not occur in children. When a child loses skills they once had, doctors look for rare genetic and metabolic disorders, some of them loosely called childhood dementia. Those are different diseases with different care.

Is Alzheimer’s preventable?

Not reliably. Nothing has been proven to prevent it. Looking after blood pressure, blood sugar, hearing, physical activity and social contact is linked to lower dementia risk in general. In a 2025 expert consensus on reusing existing drugs, shingles vaccination stood out, with 16% fewer new dementia cases among vaccinated people in the data reviewed [8]. Cannabis has not been shown to prevent Alzheimer’s.

How early signs differ from normal aging · How symptoms change by stage

Alzheimer’s early signs: how to know if you have Alzheimer’s

You cannot know for sure on your own; a memory evaluation is what tells. What you can do is notice a pattern. Everyone forgets. The early warning signs of Alzheimer’s are forgetting that keeps getting in the way, that repeats, and that friends or family begin to notice before you do. In some people a change in mood, judgment or finding words comes first.

Which of these have you noticed?

Tap the changes on the right that match what you see at home. Nothing is saved or sent.

Names

Common with age

A name escapes you and comes back an hour later.

Worth a doctor’s visit

Close friends’ or grandchildren’s names are lost and do not come back.

Keys and glasses

Common with age

Misplaced, then found by retracing your steps.

Worth a doctor’s visit

Turn up in the fridge or the oven, with no idea how they got there.

Money

Common with age

Missing one bill in a busy month.

Worth a doctor’s visit

Bills that were easy for years become confusing; odd purchases or scams slip through.

Getting around

Common with age

Needing directions to a place you rarely visit.

Worth a doctor’s visit

Getting lost on the drive to a grocery store used for years.

Conversation

Common with age

Telling the same story to the same friend twice in a year.

Worth a doctor’s visit

Asking the same question three times in ten minutes without realizing it.

What happens at a memory evaluation

A memory evaluation usually starts with a primary care doctor, who can refer you to a neurologist, a geriatrician or a memory center, a clinic that specializes in diagnosing memory disorders, often at a university hospital. Bring someone who knows you well. The visit tends to follow these steps:

  1. A conversation about what changed and when, with your companion’s view as well.
  2. A short memory test on paper or a tablet: recalling words, drawing a clock, naming animals, simple arithmetic.
  3. A review of every medicine and supplement, since several can blunt memory.
  4. Blood tests for treatable causes, then a brain scan if the picture is unclear.
  5. Biomarker tests (spinal fluid, PET or a blood test) when a firm diagnosis would change treatment [2].
How long can Alzheimer’s go undetected?

For years. Plaques and tangles start building long before anyone notices symptoms, and the first changes are easy to explain away as stress or age. Families often look back and see the signs were there well before the diagnosis.

Does Alzheimer’s make you tired?

Often, yes. Broken nights, the effort of following a conversation and low mood all drain energy, and people in later stages sleep through much of the day. Sudden heavy sleepiness is worth checking against the medicine list: sedatives, some antidepressants and anything new are common culprits.

Does Alzheimer’s make you shake?

Shaking is not a typical early sign of Alzheimer’s. A tremor next to memory problems points the doctor toward other causes, such as Parkinson’s disease, Lewy body dementia, an overactive thyroid or a medicine side effect. Muscle jerks can appear in late-stage Alzheimer’s. Any new tremor belongs on the list for the next appointment.

How Alzheimer’s differs from other causes of memory loss

Alzheimer’s vs FTD, mild cognitive impairment and ordinary memory loss

Several conditions look like Alzheimer’s from the outside, and some are treatable. Frontotemporal dementia (FTD) often starts with behavior rather than memory. Mild cognitive impairment may stay mild for years. Delirium comes on fast and usually clears once its cause is treated. Even adult ADHD can pass for early memory loss in a busy person. Choose a condition to set it next to Alzheimer’s.

A guide for the conversation with a doctor, not a way to diagnose. Only a clinical evaluation can tell these apart.

Alzheimer’s disease next to six conditions it is often confused with
What to look at Alzheimer’s Frontotemporal dementia Mild cognitive impairment Delirium Normal aging Adult ADHD Lewy body dementia
First sign Forgetting recent events and conversations Personality change, loss of tact, or trouble with language Memory or thinking slips that tests can measure Sudden confusion and poor attention Slower recall of names and words Lifelong distractibility and disorganization Vivid visual hallucinations, acting out dreams, stiffness
Speed Gradual, over years Gradual, sometimes faster than Alzheimer’s Slow; may stay stable or improve Hours to days Very slow, barely changes year to year Present since childhood, not progressive Gradual, with good and bad days
Memory New information is not stored Often fairly well kept early on Below what is expected for age, daily life intact Patchy, because attention fails Retrieval slower, but the memory is there Information never caught in the first place Attention and alertness swing more than memory
Behavior Agitation and suspicion later, sundowning Impulsive, apathetic or socially inappropriate early Usually unchanged, sometimes anxious or low Restless or drowsy, may see things Unchanged Restlessness and impatience, unchanged over life Hallucinations; very sensitive to antipsychotics
Typical age Most often later in life Often earlier, in midlife Later in life Any age, most often older and ill adults With advancing years From childhood, often noticed in adulthood Later in life
What tells them apart Memory tests plus amyloid and tau biomarkers Behavior history and frontal or temporal shrinkage on scans Tests show a change but daily life is preserved Fast onset and a treatable trigger such as infection Normal test scores for age A pattern going back to school years Hallucinations, movement signs and fluctuations early

Schizophrenia sometimes enters the question because both can bring paranoia. The difference is timing: schizophrenia usually begins in early adulthood, while suspicion in Alzheimer’s appears late, alongside memory loss. ALS (amyotrophic lateral sclerosis) is a different story again: it destroys the nerve cells that move muscles, and memory is usually spared.

How Alzheimer’s moves through its stages

Alzheimer’s stages and the symptoms that change

Most doctors speak of three stages of Alzheimer’s disease: early (mild), middle (moderate) and late (severe) [2]. The borders blur, and two people with the same diagnosis can move through them at very different speeds. Many families find the middle stage the longest and the most demanding. A stages timeline in years would be a guess for any one person, so this guide does not give one; the doctor who follows the patient can say far more from their own history.

Follow one kind of symptom

The buttons narrow the table to one column so you can read a single problem from mild to severe. The table describes stages; it cannot place a person in one.

Alzheimer’s stages and symptoms. A tag marks the symptoms cannabinoid studies have looked at.
Stage Memory & thinking Behavior & sleep Eating & weight Daily care
Early (mild) Recent conversations slip away; the same question comes back; words and objects go missing; bills and planning take longer. Pulling back from friends, low mood or worry; in some people, nights begin to break up. Mostly unchanged; meals may be skipped by someone who lives alone. Independent with lists and reminders; money and driving need a second pair of eyes.
Middle (moderate) Loses track of date and place, may not recognize familiar faces, can get lost in a known neighborhood. Agitation, suspicion, wandering, evening restlessness, nights and days swapped; hallucinations may begin. studied in cannabinoid research Forgets meals or eats twice; taste changes; weight can start to drop. studied in cannabinoid research Needs help with dressing, bathing and medicines; often should not be left alone.
Late (severe) Few or no words, cannot follow a conversation, little awareness of surroundings. Agitation may continue or give way to apathy; sleeps through much of the day. studied in cannabinoid research Chewing and swallowing become hard; clear weight loss; choking risk. studied in cannabinoid research Help with every activity, often around the clock; many families turn to a nursing home or memory care.

The tags matter for what comes later. Cannabinoid research has looked at behavior, sleep and appetite in the middle and late stages, and those are also the stages where an older body tolerates added medicines least well.

The 7-stage scale: GDS and FAST

Some clinicians use a finer, seven-step scale. The best known is the Global Deterioration Scale described by psychiatrist Barry Reisberg, with a companion called FAST (Functional Assessment Staging) that tracks everyday abilities; a FAST score is simply the stage a person has reached. Stages 1 to 3 come before a dementia diagnosis, 4 matches the early stage, 5 and 6 the middle, and 7 the late stage. Sources draw these lines slightly differently.

  1. Stage 1 · No impairment

    Memory and thinking are normal. Changes may already be starting in the brain, but nothing shows.

  2. Stage 2 · Very mild decline

    The person notices lapses, such as a lost word or misplaced glasses, that others do not see and tests do not pick up.

  3. Stage 3 · Mild decline

    Family and coworkers start to notice. Memory tests show a change. This often corresponds to mild cognitive impairment.

  4. Stage 4 · Moderate decline (early Alzheimer’s)

    Recent events fade, money and complex tasks become hard, and a diagnosis is usually made here.

  5. Stage 5 · Moderately severe decline

    Help is needed choosing clothes and keeping track of the day. Address and phone number may be forgotten, while close family is still known.

  6. Stage 6 · Severe decline

    Help with bathing, dressing and the toilet. Agitation, wandering, suspicion and broken sleep are most common in this stage, and a spouse may be mistaken for a stranger.

  7. Stage 7 · Very severe decline

    Speech dwindles to a few words, then walking, sitting up and swallowing are lost. Care is around the clock.

End stage and end of life

In the last stage of Alzheimer’s the body, not only memory, is affected. Swallowing problems lead to choking and pneumonia, immobility to pressure sores and infections, and weight falls even with careful feeding. Comfort becomes the main goal: mouth care, gentle positioning, treating pain and keeping a familiar voice nearby. Hospice teams care for people with end-stage dementia at home or in a facility and support the family too; a primary care doctor can make the referral.

Answer a few questions about your situation

What treatments exist for Alzheimer’s today?

Alzheimer’s medicines today fall into three groups: drugs that support memory and thinking for a while, antibody infusions that modestly slow the disease in its early stage, and medicines for behavior symptoms [2]. None of them cures it. Cannabinoids sit outside all three groups, as something studied rather than approved.

Main treatment options for Alzheimer’s disease in the United States
OptionWhat it is forHow it is given
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) Support memory and thinking by keeping more acetylcholine, a signaling chemical, available in the brain [2] Tablets or liquid; rivastigmine also comes as a daily skin patch, useful when swallowing pills is a struggle
Memantine Moderate to severe stages, alone or with a cholinesterase inhibitor [2] Tablets, capsules or liquid
Anti-amyloid monoclonal antibodies (lecanemab, donanemab) Early Alzheimer’s with confirmed amyloid; clear plaques and modestly slow decline [2] Infusion into a vein at a clinic, with repeat MRI scans to watch for brain swelling or small bleeds
Brexpiprazole The antipsychotic approved for agitation linked to Alzheimer’s dementia; carries warnings for older adults [2] Tablets, after non-drug steps have been tried
Escitalopram (studied, not approved for this) Tested for agitation in a phase 3 trial of 173 people; no clear benefit over placebo (difference -0.08, 95% CI -0.21 to 0.06), with more falls and diarrhea [1] Tablets, at the doses used in the trial
Cannabinoids Studied for agitation, sleep and appetite; not approved for Alzheimer’s [9] Prescription capsules (dronabinol, nabilone) or dispensary products with a medical card

How is Alzheimer’s treated in China or Europe? The same drug groups form the core almost everywhere. What differs is access: the antibody infusions are approved in some countries and not in others, and in China many families combine standard medicines with traditional herbal remedies, which carry their own interaction questions.

Whatever is already prescribed stays in place. Stopping a memory medicine or an agitation medicine to make room for cannabis is a change only the prescribing doctor should make.

What one careful agitation trial teaches about any new medicine

The escitalopram trial is worth a closer look, not because it involves cannabis (it does not), but because it shows how a well-run test of an agitation medicine in Alzheimer’s actually goes. People took the antidepressant at up to 15 mg a day for 84 days, alongside a structured support program for their caregivers [1]. The trial aimed to enroll 392 people and reached 173, so it could not rule out a smaller benefit than the one it was built to detect [1]. On its main measure it found no clear improvement, and falls and diarrhea were more common on the drug [1]. The authors went further and advised against using it for agitation in Alzheimer’s, because of heart rhythm (QTc) concerns and the missing benefit [1].

Three lessons carry over to cannabis. A medicine that sounds gentle can still add falls in a frail person. A trial that falls short of its planned size leaves the question open rather than answered. And a caregiver program running in the background can make both groups look better, which is why a change at home is easier to credit to a new pill than it should be.

Before anything new is added: questions for the prescribing doctor

  • Which symptom are we treating, and how will we know in two or four weeks whether it is better?
  • Have the non-drug steps been tried long enough: daytime light, a steady routine, pain and constipation checked, hearing aids and glasses in use?
  • Could a current medicine be causing the problem, for example an allergy pill or a bladder medicine that adds confusion?
  • What side effect would make us stop, and who decides that at home?
  • If a cannabinoid is discussed, which of the current medicines need a closer look first?

What helps at home without any medicine

Best care for Alzheimer’s patients at home

Before any medicine, small changes to the day often do the most. They cost nothing, carry no interactions, and doctors usually ask whether they were tried before adding a drug. The lists below are about the person with Alzheimer’s: their routine, their plate, their house.

Sleep and evenings

  • Same wake-up time every day, and bright daylight or a walk in the morning.
  • Keep naps short and early; no caffeine after lunch.
  • Turn the lights up before dusk and close curtains so shadows and reflections do not frighten.
  • A quiet, familiar evening routine: music they love, a warm drink, the same chair.
  • A night light on the way to the bathroom, and a check for pain, a full bladder or hunger when they wake.

Meals

  • One or two foods on the plate at a time, on a plate that contrasts with the food and the table.
  • Finger foods when cutlery becomes confusing.
  • Small meals and snacks through the day, and water offered often.
  • Eat together; people copy what they see.
  • Coughing at meals or pocketing food in the cheek calls for a swallowing check by the doctor.
  • Weigh once a week and write it down for the next appointment.

Safety at home

  • Clear loose rugs and cables; add grab bars in the bathroom.
  • Knob covers or an automatic shut-off on the stove.
  • Car keys out of sight once driving is no longer safe.
  • Medicines, cleaning products and any cannabis locked away.
  • An ID bracelet and door chimes for someone who wanders.

Looking after the person who gives the care

Caring for someone with Alzheimer’s is long, broken-up work, and it shows in the carer’s own health. A 2026 systematic review found that parents caring for an older relative had about seven times the odds of non-caregivers to start or increase alcohol, tobacco, cannabis or other substance use (odds ratio 7.19, 95% CI 5.87-8.83) [10]. The risk was higher still in carers who already had anxiety (relative risk 2.21, 95% CI 1.26-3.88) or depressive symptoms (relative risk 2.04, 95% CI 1.17-3.55), and in younger carers aged 18 to 44 (relative risk 4.43, 95% CI 1.92-10.19) [10].

None of that is a judgment. It is a reason to plan for the carer as deliberately as for the patient: a named person who can take over for an evening, a regular night of unbroken sleep, a doctor’s appointment of your own, and an honest look at how much you drink or smoke to get through the day. If cannabis is being considered for the person with Alzheimer’s, it belongs to them and their physician; it is not a shared supply, and it is not a coping tool for the household.

  • Write down one task someone else could take each week, and ask for it by name.
  • Keep a short daily log of sleep, meals, mood and any doses given; it helps the doctor and shares the load between relatives.
  • Tell your own doctor that you are a caregiver; it changes what they ask about.
  • Use respite before you need it, not after a crisis.

Support is easier to find than many families expect. The Alzheimer’s Association runs a free helpline that answers day and night and lists local support groups, including groups for people in the early stage [11]. The National Institute on Aging publishes plain-language guides on daily care and on finding services nearby [2]. A memory center can also connect families with social workers and day programs, and respite care gives the person at home a few hours or days off.

See whether cannabis is worth raising for your situation

Could medical cannabis be worth discussing for these symptoms?

Fifteen quick questions about the person with the symptoms: the diagnosis, what is hardest day to day and which medicines they take. You get a short summary of how that fits the research and what to take to a physician. Your answers stay in this browser.

15 questions · about a minute · your answers stay in this browser

Question 1 of 15

How old is the person with the symptoms?

Why cannabis comes up in Alzheimer’s care: the endocannabinoid system

Because the brain has its own cannabinoid system, and Alzheimer’s changes it. That is the scientific reason researchers keep testing these compounds, and it explains why the question is less strange than it sounds.

  1. What the system does

    The endocannabinoid system is a set of signaling molecules made by the body, such as anandamide, and the receptors they bind to. CB1 receptors, found mostly on nerve cells, tune memory, mood, appetite and sleep. CB2 receptors sit mainly on immune cells, including the brain’s own, and calm inflammation.

  2. What changes in Alzheimer’s

    In brain tissue from people who died with Alzheimer’s, CB1 receptor levels were lower in the hippocampus and in two areas of the cortex than in people without the disease, and the same drop appeared in mouse models [3].

  3. Why researchers test cannabinoids

    If the system is weakened, adding cannabinoids or protecting the body’s own might restore some balance. THC acts on CB1; CBD works through several other targets. Whether that helps patients is a separate question, and so far the answer is limited.

The link reaches people without dementia too. In older adults free of dementia, blood levels of certain endocannabinoids tracked with scores on thinking tests, mostly in women and in carriers of the APOE ε4 gene variant, the best-known genetic risk factor for Alzheimer’s [6]. FAAH, the enzyme that breaks anandamide down, is the reason some labs try to raise the body’s own cannabinoids instead of adding THC. The blood study was a single snapshot, so it shows a link, not a cause.

Which cannabinoids have been studied?

Four kinds of product appear in this research, and each behaves differently. THC is the part of cannabis that produces a high. CBD does not, but it changes how the liver handles other drugs. Products combine both in different ratios. Dronabinol and nabilone are prescription capsules built around THC.

Cannabinoids studied in Alzheimer’s research. The two groups are listed separately and are not ranked against each other.
SubstanceWhat was studiedType of studyWhat came out
Dispensary products, available with a medical card where state law allows
THC Agitation and behavior in patients; amyloid and tau in mice, including a tiny 0.002 mg/kg dose given in the nose [12]. Small trials; animal studies Mixed in people. In animals the effect depends on dose: 10 mg/kg switched on inflammatory cells in the brain [13].
CBD Amyloid and memory in mouse models, from 5 mg/kg up to 100 mg/kg a day [12][14]. Mostly animal studies Less amyloid and better memory scores in some mice; hardly any patient data. Slows the liver’s handling of other medicines [13].
THC with CBD A low-dose balanced extract for thinking and memory, and a 26-week low-dose oral THC with CBD trial [15][12]. Small randomized trials Mixed; the memory trial enrolled fewer patients than it needed [15].
Prescription medicines, filled at a pharmacy, not bought with a card
Dronabinol (Marinol, Syndros) Agitation in Alzheimer’s, raised step by step to at most 10 mg a day in one trial [12]. Clinical trials Not approved for dementia. FDA-approved for chemotherapy nausea and for weight loss in AIDS [9].
Nabilone (Cesamet) Behavior symptoms of dementia, among the synthetic cannabinoids tested. Small trials Not approved for dementia. FDA-approved for chemotherapy nausea [9].

What these compounds did for symptoms · How the endocannabinoid system works

Can cannabis help with Alzheimer’s symptoms?

Possibly, for some symptoms in some people. The trials behind that answer are few and small and point in different directions, so cannabis is a fair question to raise with a physician, not an established treatment. Reviewers who went through these trials call them promising and not ready for routine prescribing [15][12].

Three symptoms have drawn nearly all the attention. Pick one to see what was tested.

Agitation

What was tested

Dronabinol, prescription THC, increased gradually to no more than 10 mg a day in people with Alzheimer’s and agitation [12].

How strong

A handful of small trials using different products and doses, with results that do not line up [12].

Bottom line

The symptom studied most, and still open. Sleepiness was a frequent side effect.

Sleep

What was tested

Mostly measured on the side of behavior trials. Sleepiness appears in the safety reports on THC and CBD in older adults [13].

How strong

None of the trials cited here was designed around sleep in Alzheimer’s.

Bottom line

Feeling drowsy is not the same as sleeping better at night. More on cannabis and sleep.

Appetite & weight

What was tested

Dronabinol is FDA-approved for poor appetite and weight loss in AIDS [9]. In Alzheimer’s it was studied chiefly for behavior.

How strong

No trial cited here made weight in Alzheimer’s its main goal.

Bottom line

A reasonable thing to ask about, not a proven benefit in dementia.

How big is the effect?

Nobody can put a number on it yet. Measuring the size of an effect needs several trials that report the same outcome with a margin of error, and for cannabinoids in Alzheimer’s those trials do not exist. For scale, the escitalopram trial for agitation, which did report one, found a difference from placebo of -0.08 with a likely range of -0.21 to 0.06; the range crosses zero, which means no clear benefit [1]. The most telling cannabinoid number is about trial size:

Length matters as much as size. Most of these trials ran for weeks; the longest low-dose oral THC plus CBD trial described in a 2026 review lasted 26 weeks [12], which is still short next to an illness that unfolds over years. A benefit that shows up in the first month can fade, and a side effect such as a fall may only appear once someone has taken a product for months.

In practice a physician may consider a cannabinoid for agitation or poor sleep alongside the usual steps, never instead of them, and will weigh it against drowsiness, falls and the medicines already on the list.

Safety for older adults · Interactions with dementia medicines

Can cannabis stop or reverse Alzheimer’s?

No. No study in people shows that cannabis or any single cannabinoid stops, slows or reverses Alzheimer’s disease, and no trial has seen memory improve and stay improved. Is Alzheimer’s reversible by any means? The disease itself is not. A bad patch caused by an infection, poor sleep or a side effect can lift once that cause is treated, and that is easy to mistake for the disease going backward.

The hopeful headlines come from laboratory animals, and the gap between those results and patients is wide.

In mice

What was tested

URB597, a compound that blocks FAAH (the enzyme that breaks down anandamide), at 5 mg/kg for 5 months in male mice bred to grow amyloid plaques [16]. Separately, CBD at 100 mg/kg a day in 22 male model mice [14].

What changed

Fewer plaques and less inflammation in the FAAH study, in experiments on animals; mixed results across memory and brain measures with high-dose CBD.

What it means

A lead for future trials, shown in animals only.

In people

What was tested

THC, CBD and mixtures, chiefly for agitation, plus one low-dose THC-CBD extract aimed at thinking and memory in 28 analyzed patients [15].

What changed

No trial showed slower decline. Effects on symptoms were mixed.

What it means

In patients, cannabinoids are discussed as symptom relief at most; nothing suggests they change where the illness is heading.

Animal results do not transfer to people. A mouse model carries one engineered version of the disease, lives a couple of years, and receives doses per kilogram that do not convert into a human dose.

How the mouse study was done

The team raised anandamide in two ways: by deleting the FAAH gene and by giving URB597. With more anandamide around, CB1 receptors switched off the gene for BACE1, the enzyme that cuts the amyloid precursor protein into the sticky fragments that build plaques. Plaque density fell (p = 0.0002), soluble amyloid-beta 42 dropped, and a drug that blocks CB1 undid the effect, which ties the result to that receptor [16]. All the animals were male, so it is not even known whether females respond the same way.

How much weight each kind of study can carry

What the research shows, from strongest to weakest

In short: trials of cannabinoids in people with Alzheimer’s are few and small, and their results are mixed. Every report of slowing the disease comes from animals or cells.

A randomized trial, where patients are assigned by chance to the treatment or a placebo, can answer whether something helps. A study that only observes people can show a link. A mouse experiment can show a mechanism. The table puts what exists for Alzheimer’s on each of those rungs.

Three levels of evidence, strongest at the top
LevelWhat exists for Alzheimer’sWhat it can and cannot tell you
Trials in people Small randomized trials of THC, CBD and dronabinol, mostly for agitation [12]; one THC-CBD extract trial with 28 analyzed patients [15]. The escitalopram trial of 173 people is a background comparison, not a cannabis study [1]. Can show an effect on a symptom and its side effects; so far too small and too short to show a clear benefit.
Studies that observe people Brain tissue showing fewer CB1 receptors [3]; past cannabis use and later thinking in UK Biobank adults, with mixed results [17]; who uses cannabis in a memory clinic [18]. Genetic studies sit here as background [4]. Shows links, not cause and effect. Past or heavy use is not the same as supervised medical use.
Animal and lab work Mouse and cell studies of CBD, THC and the FAAH enzyme, reporting less plaque and inflammation [16][14][19]. Explains why scientists are interested. Says nothing yet about what happens in patients.

What kinds of studies is this evidence built on?

How to read it: one row per type of study on cannabinoids and Alzheimer’s; a longer bar means more published studies of that type. The strongest designs are listed first. Gray bars, marked background, are reviews, animal work and lab work: useful for ideas, unable to show whether patients benefit.

By study design

  1. Meta-analyses15
  2. Systematic reviews32
  3. Clinical guidelines1
  4. Randomized trials23
  5. Crossover randomized trials23
  6. Other clinical trials40
  7. Cohort studies33
  8. Case-control studies11
  9. Cross-sectional studies29
  10. Surveys4
  11. Case reports20
  12. Narrative reviews (background)278
  13. Animal studies (background)269
  14. Cell and lab studies (background)157

The three longest bars are all background work, which is why trials in people still decide the answer, and why that answer remains open.

By who was studied

  1. People given a treatment57
  2. People observed, not treated281
  3. Whole populations15
  4. Animals (background)72
  5. Cells and molecules (background)181
  6. Research methods (background)3
  7. Not classified (background)344

Studies that treated patients are a small slice next to those that only watched them, so most of what is known is a link rather than proof that cannabinoids work.

Show as a table
Published studies on cannabinoids and Alzheimer’s by design
DesignStudies
Meta-analyses15
Systematic reviews32
Clinical guidelines1
Randomized trials23
Crossover randomized trials23
Other clinical trials40
Cohort studies33
Case-control studies11
Cross-sectional studies29
Surveys4
Case reports20
Narrative reviews (background)278
Animal studies (background)269
Cell and lab studies (background)157
Published studies on cannabinoids and Alzheimer’s by who was studied
Who was studiedStudies
People given a treatment57
People observed, not treated281
Whole populations15
Animals72
Cells and molecules181
Research methods3
Not classified344

Browse the studies yourself

These are the Alzheimer’s papers cited above, each in a sentence or two. Null results and papers that turned out not to test cannabis are kept and labeled, not dropped.

2026 · Randomized trial (commentary) · 28 patients

A low-dose THC-CBD extract for memory and thinking

The trial analyzed 28 patients when it needed 37; results were mixed, and the commentator judged it not ready for prescribing [15].

2025 · Randomized phase 3 trial · 173 people Background, not a cannabis study

Escitalopram for agitation in Alzheimer’s

The antidepressant did no better than placebo on the main measure at 12 weeks (p = 0.28), and falls happened more often on the drug [1].

2026 · Post-mortem case-control study

Fewer cannabinoid receptors in Alzheimer’s brains

CB1 receptors were scarcer in the hippocampus and two cortical regions of people who had Alzheimer’s, and in model mice [3].

2026 · Narrative review

From animal results to patients

CBD and THC look encouraging in animals, but trials in people are few, small and use different products; one raised dronabinol to 10 mg a day [12].

2026 · Narrative review

Dose and the aging brain

Low and high doses of THC can act in opposite directions in older brains, and CBD can raise blood levels of other medicines by slowing liver enzymes [13].

2025 · Animal study

Raising anandamide in plaque-forming mice

Blocking the FAAH enzyme for 5 months cut plaque density and brain inflammation in male mice [16].

2025 · Cohort study (UK Biobank)

Earlier cannabis use and thinking in later life

Links between a history of cannabis use and later test scores in older adults were mixed, pointing clearly neither to harm nor to benefit [17].

2025 · Cross-sectional study

Cannabis use among memory clinic patients

A Canadian cognitive clinic surveyed how many of its patients used cannabis and what went with it; it did not test whether use helped [18].

2024 · Cross-sectional study

The body’s own cannabinoids and memory after 60

Blood endocannabinoid levels tracked with thinking scores in dementia-free adults, mainly in women and APOE ε4 carriers [6].

2026 · Survey · 143 and 117 patients Background, not a cannabis study

Psychiatric patients’ views before and after legalization

Fewer named the law as their reason to stay away from cannabis after legalization (11.2% before, 1.7% after), while worries about mental health held steady [20].

2025 · Cohort study Background, not a cannabis study

What memory problems cost older patients

Cognitive impairment added about $6,883 a year in health costs for women (95% CI $3,461-$10,305) and $7,276 for men (95% CI $3,298-$11,254) [7].

2025 · Cohort study Background, not a cannabis study

Being told you have brain amyloid

Learning that a scan showed raised amyloid was not tied to suicidal thoughts years later in healthy volunteers (odds ratio 1.6, 95% CI 0.76-3.37, no clear difference) [21].

2025 · Imaging cohort Background, not a cannabis study

Seeing synapse loss on an ordinary MRI

A deep learning model generated synapse-density PET images from routine MRI scans, a possible cheaper way to track the disease [22].

2020 · Systematic review Background, not about Alzheimer’s

Medical cannabis in movement disorders

Across 22 studies, mostly in Huntington disease, only 78 Huntington patients were available, so the authors leaned on data from other conditions [23].

2019 · Systematic review Background, not about Alzheimer’s

Medical cannabis for mental disorders

Evidence for cannabinoids in psychiatric conditions was patchy; CBD was tried as an add-on to antipsychotics in some trials [24].

2016 · Systematic review Background, not about Alzheimer’s

Medical marijuana in psychiatric indications

Found weak evidence overall and noted that alcohol, benzodiazepines and opioids add to the thinking and driving impairment caused by cannabis [25].

2026 · Systematic review

Substance use among people caring for older adults

Parents caring for an older relative were far more likely to start or increase substance use than non-caregivers (odds ratio 7.19, 95% CI 5.87-8.83) [10].

2026 · Narrative review Background, not a cannabis study

Medicinal plants for Alzheimer’s

Reviewed 174 articles on 14 well-studied plants; human evidence is thin, and the authors warn about herb-drug interactions in older adults [26].

2026 · Narrative review Background, not a cannabis study

Diet supplements in Alzheimer’s trials

A critical look at dietary compounds tested in clinical trials found no consistent benefit for thinking [27].

2026 · Narrative review Background, not a cannabis study

Targeting amyloid clumping and inflammation

A survey of approaches aimed at amyloid and brain inflammation, most still in the lab [28].

2025 · Expert consensus Background, not a cannabis study

Existing drugs worth retesting for Alzheimer’s

An expert panel ranked candidates for repurposing; shingles vaccination was linked to 16% fewer new dementia cases [8].

2026 · Genome-wide meta-analysis Background, not a cannabis study

91 genetic regions tied to Alzheimer’s

Pooled 977,514 people; 16 of the regions were new, pointing to amyloid, tau, fats, immunity and the brain’s immune cells [4].

2025 · Genome-wide meta-analysis (preprint) Background, not a cannabis study

A genetic score that predicts brain changes

The top tenth of the score had about twice the odds of advanced tau (2.05, 95% CI 1.47-2.85) and of heavy plaques (1.96, 95% CI 1.39-2.78) [5].

2025 · Multi-ancestry genetic meta-analysis Background, not a cannabis study

Risk genes across ancestries

Analyzing 56,241 people of several ancestries turned up risk regions that single-ancestry studies had missed [29].

2025 · Genetic (Mendelian randomization) study

Does substance use speed up biological aging?

Genetic signals for cannabis use disorder were tied to small shifts in aging measures, much smaller than those for tobacco use disorder [30].

2026 · Animal study · 22 male mice

High-dose CBD in model mice

CBD at 100 mg/kg a day, started at 7.5 months of age, gave mixed results across behavior and brain measures [14].

2026 · Animal study

How CBD may protect nerve cells

In mice, CBD switched on TrkB, a receptor that supports nerve cell survival, and eased Alzheimer-like damage and memory loss [19].

2026 · Animal study Background, not a cannabis study

A gut bacterium and CB2 signaling

Four weeks of a Lactobacillus strain reduced oxidative stress in nerve cells of model mice through CB2 receptors [31].

2026 · Animal study Background, not a cannabis study

A blood pressure drug and brain inflammation

Valsartan lowered amyloid-beta 42 by 53% and acetylcholinesterase activity by 73% in inflamed mice, partly via the endocannabinoid system [32].

2026 · Animal study Background, not about Alzheimer’s

Gut-made anandamide and memory after alcohol

In mice, anandamide produced by gut bacteria carried the benefit of urolithin A on alcohol-related memory and social problems [33].

Who reviews this page · The research library

Forms of cannabis when the patient can’t manage dosing alone

In Alzheimer’s, the person taking a product often cannot count doses, remember the last one or say how they feel an hour later. That changes how each form of cannabis looks. Smoking and vaping are the forms most people picture, but medical products are also eaten, swallowed as capsules, dropped under the tongue, sprayed into the mouth, rubbed on skin or worn as a patch. Some risks belong to one form; others come with any form; a few come from sharing a device. None of this recommends a form: that choice is made with a physician.

Which form are you asking about?

The general card stays open; tap a form to add what changes with it.

Smoking: joints, blunts, pipes, bongs

Burning plant matter sends smoke into lungs that may already struggle with swallowing and chest infections. How much THC arrives in each puff cannot be read off a label. A lighter in the hands of someone confused is a fire and burn hazard of its own.

Vaping and dabbing

Dry-herb vaporizers, oil cartridges, pens and dabbing rigs heat rather than burn, yet the warm aerosol still lands in the airways. Wax, shatter and rosin used for dabbing are concentrated enough that a small mistake becomes a large dose, and a pen is easy to pick up again without remembering the last puff.

Shared devices

Germs travel on mouthpieces. For a frail person with Alzheimer’s, a cold or flu picked up from a shared pipe or vape can turn into a chest infection and a hospital stay.

Edibles, drinks and capsules

Gummies, chocolates, drinks, swallowed oils and capsules involve no smoke. They take an hour or more to act and last for hours, and the liver works on them first; a 2026 review puts the share of swallowed THC that reaches the blood at about 6% [13]. The danger for someone with memory loss is the second helping: “I haven’t had any yet” may be sincere and wrong. Gummies also look like candy to a confused adult.

Tinctures and mouth sprays

Oils and tinctures held under the tongue, and sprays into the cheek, are counted in drops or puffs that a helper can log. They keep away from the lungs, but part of each dose is swallowed, and certain pharmaceutical oral solutions contain alcohol, which rules them out alongside disulfiram or metronidazole [13].

Creams, balms and patches

Creams and balms work mainly on the patch of skin where they are rubbed in and do not reach brain symptoms. Transdermal patches are different: they release cannabinoids into the bloodstream, so drowsiness and interactions are the same questions as for anything swallowed. A patch can also be peeled off, moved or doubled by someone who does not remember it.

Suppositories

Rarely used. They bypass swallowing, but what reaches the blood still acts on the brain, and giving them raises questions of dignity and consent that a physician should talk through.

Prescription capsules: dronabinol and nabilone

These come with a printed dose, a pharmacy label and a prescriber who follows up, which makes them easier to track at home. They are prescribed, not bought with a medical card, are not approved for dementia [9], and bring the same sleepiness and fall risk as THC.

True of every form

  • THC in any form can bring sleepiness, confusion and unsteadiness, and with them falls.
  • Sedation from cannabis stacks on top of sleeping pills, anxiety medicines and some dementia drugs.
  • CBD and THC pass through liver enzymes shared with many prescriptions, so blood levels of those medicines can shift.
  • Read the THC and CBD amounts on the label, not the brand name: a THC risk does not carry over to a CBD-only product, and the reverse is also true.
  • Someone else should keep the supply and a written dose log.
  • No driving after any use.
All forms as a table
What each form avoids and what it keeps; forms that are not inhaled have their own rows
FormWhat it avoidsWhat it keeps
SmokingA delayed onsetSmoke in the airways, fire risk, shared devices, a dose that cannot be measured, every effect of THC
Vaping and dabbingBurning plant matterWarm aerosol in the airways, very strong concentrates, shared devices, every effect of THC
Edibles and capsulesSmoke, aerosol, shared devicesSlow onset and long effect, the second-helping trap, liver processing, interactions
Tinctures and spraysSmoke, aerosol, shared devicesEffects on the brain, part of the dose swallowed, alcohol in some solutions, interactions
Creams and balmsEffects on the brainSkin reactions; no help for brain symptoms
Transdermal patchesSmoke, aerosol, swallowingEffects on the brain, interactions, falls, a patch that can be moved or doubled
SuppositoriesSwallowing, airwaysEffects on the brain, interactions, consent questions
Prescription capsulesUnknown product contentSleepiness, dizziness, interactions; not approved for dementia

What researchers still cannot answer

What science doesn’t know yet

Here the unknowns outweigh the knowns. The authors of these studies flag the same weaknesses again and again, and they are worth knowing before anyone decides anything.

  • Trials are too small to detect a real difference. The THC-CBD memory trial analyzed 28 patients when it needed 37 [15]; even the escitalopram trial reached 173 of its planned 392 [1].
  • Treatment periods run for weeks, while Alzheimer’s unfolds over years, so long-term benefit and long-term harm are both unknown [26].
  • There is no agreed product, dose or THC to CBD ratio. Studies use different extracts, which makes them hard to compare or repeat [13].
  • Direct trial data in people of the age most affected are scarce [13], and nobody has studied cannabinoids specifically in late-stage Alzheimer’s or over long-term use.
  • Most results still come from animals and cells [26], and key mouse experiments used males only [16][14].
  • Genetic studies of risk have limited power for small effects, and the genetic score explains only part of who develops the disease [5].
  • Survey data on how patients feel about cannabis come from single clinics, use questionnaires that were never validated, and leave out people with psychosis or addiction, who are exactly the patients a physician worries about most [20].
  • Reviews of plant-based treatments for Alzheimer’s keep finding the same pattern: much preclinical promise, few human trials, short treatment periods and products that are not standardized [26].

How to read a headline about cannabis and Alzheimer’s

News stories rarely say which kind of study they describe, and that one detail decides how much the result is worth. Five questions sort most of them in a minute.

  1. Who was studied? Mice, cells in a dish or people. A result in animals is a reason to run a trial, not a reason to change care.
  2. How many people, and for how long? A few dozen patients over a few weeks cannot show whether a benefit lasts or a rare harm exists.
  3. Was there a comparison group? Families and staff notice change when they expect it. Without a placebo group, an improvement may simply be the extra attention.
  4. Which product and which dose? A pharmaceutical capsule with a measured amount of THC is not the same as a dispensary gummy, and neither is the same as a mouse injection.
  5. What was actually measured? Less amyloid in a brain scan or a tissue sample is not the same as better memory, and calmer behavior is not the same as a slower disease.

If the article cannot answer most of these, treat it as a question to bring to the appointment, not an answer.

The side effects that matter most after 70 · The physicians who review this information

Safety for older adults: side effects and who should not use cannabis

A side effect that is a nuisance at 40 can be a hip fracture at 82. People with Alzheimer’s have less reserve, often take several medicines and may not be able to describe what they feel. Reviewers warn specifically against early, unsupervised use of unregulated cannabis products in Alzheimer’s care, because of sleepiness and paranoia in this frail group [15][12].

Drowsiness

The effect reported most often in older adults taking THC or CBD [13]. A sleepier afternoon can pass for “calmer” while the person eats and moves less.

Confusion

Disorientation is reported with cannabinoids in older people [13]. In someone already confused, the drug and the disease are hard to tell apart.

Paranoia

Seen in trials in people with Alzheimer’s [15]. Suspicion is already part of the illness, and THC can sharpen it.

Falls

Sleepiness, unsteadiness and a drop in blood pressure on standing add up. Falls also rose on the antidepressant tested for agitation [1], a reminder to ask about falls with any new medicine.

Dizziness

Common across cannabinoid studies, together with sedation and slowed thinking [13]. Getting out of bed at night is the riskiest moment.

Driving

THC slows reactions, and alcohol, benzodiazepines or opioids make that worse [25]. Anyone using it should not drive; many people with Alzheimer’s should already have stopped.

Why the same dose can land differently

Swallowed THC is absorbed poorly and unevenly: only about 6% of an oral dose reaches the bloodstream, according to a 2026 pharmacology review [13]. That small share varies from person to person and from meal to meal, and the liver turns part of it into a second active compound. The practical result is that two people taking the same capsule can feel very different effects, and the same person can feel more on a day they ate less.

The same review stresses that dose does not work in a straight line. In animal experiments a tiny THC dose of 0.002 mg/kg calmed brain inflammation, while 10 mg/kg given by injection did the opposite and switched on inflammatory cells in the brain [13]. Those are mouse doses and they do not convert into a human prescription, but they explain why reviewers keep repeating that more is not better in older brains [13].

  • Swallowed products take a long time to act. A second dose taken because “nothing happened yet” is a common route to oversedation.
  • One person gives the doses and writes each one down, so nothing is doubled between relatives or shifts.
  • Any change in dose is agreed with the physician, never adjusted on a hunch after a bad evening.

When to call a doctor right away

  • Confusion that is suddenly worse, or new hallucinations.
  • A fall, especially with a blow to the head or pain on standing.
  • Sleepiness so deep that the person is hard to wake.
  • Fainting, chest pain, or a racing or irregular heartbeat.
  • Vomiting, or refusing food and drink for a day.

Heart rhythm deserves its own note. Any new medicine for agitation is worth an ECG question when someone has a known rhythm problem, because agitation drugs have raised QTc concerns in trials [1]. That finding comes from escitalopram, not from cannabis.

Who should not use cannabis · Check the medicine list

Who should not use cannabis for Alzheimer’s symptoms

For some people with Alzheimer’s the answer is “not now” or “not at all.” Dementia trials usually exclude these groups, so nothing shows cannabis is safe for them.

  • Anyone with a history of psychosis, meaning hallucinations or delusions that dementia does not explain; THC can make them worse. See cannabis and psychosis. Even surveys about cannabis attitudes exclude these patients [20].
  • Someone already on several sedating medicines, such as benzodiazepines, sleeping pills or opioids [25].
  • A person who has fallen more than once in recent months.
  • Anyone with severe heart or liver disease, where a physician needs to weigh any new drug carefully.
  • Pregnancy or breastfeeding; trials exclude it and THC reaches the baby.
  • New, unexplained confusion that has not yet been checked for infection, dehydration or a medicine problem.

“Not now” and “not at all” are different answers. A recent fall, an untreated infection or a medicine change in progress can push the conversation back by a few weeks while things settle. A history of psychosis, or a list of sedating drugs that cannot safely be reduced, may close it altogether. Either way, the physician should explain which one applies and why, so the family knows whether to come back.

A “no” to cannabis is not a “no” to help. The same appointment is a chance to ask what else could ease the evenings, the sleep or the appetite, and to bring those questions back to the neurologist or family doctor who knows the person best.

How the medical evaluation works · Interactions to discuss

Drug interactions to discuss with a neurologist or geriatrician

For someone with Alzheimer’s, the medicine list decides more than the diagnosis does. Below is what the studies recorded, marked by the kind of evidence behind it. It is not a full list, and the physician checks each medicine one by one.

What is on the medicine list?

Take the pharmacy printout or the labels on the bottles and tap everything that applies; the matching entries open below.

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) mechanism only

Some plant compounds, cannabinoids among them, may add to the side effects of these memory medicines: nausea, a slow pulse, vivid dreams [26]. The concern rests on how the drugs act, not on patient data. Memantine was not named in these studies. Never stop a memory medicine to try cannabis.

Benzodiazepines, sleeping pills and opioids clinical data

Lorazepam, alprazolam, zolpidem-type sleeping pills, opioids and alcohol add their sedation to cannabis. In clinical data the combination worsened thinking and driving more than cannabis alone [25], and a 2026 review flags the same sedative overlap [26]. Together they raise the risk of confusion, slowed breathing and falls. Read more on mixing cannabis and Xanax.

Antipsychotics and antidepressants clinical data

In psychiatric trials outside dementia, CBD was given on top of antipsychotics [24]; that is not evidence of safety in an 85-year-old with Alzheimer’s. Many antipsychotics and antidepressants are cleared by the same liver enzymes that CBD and THC use, so levels can change [13]. The physician reviews each drug by name.

Clobazam and other seizure medicines clinical data

Adding CBD raised the active form of clobazam four- to five-fold, because CBD blocks the liver enzymes that clear it [13]. Seizures are more common in people with Alzheimer’s, so this pairing is a real possibility, not a theory.

Disulfiram or metronidazole clinical data

Some pharmaceutical-grade oral cannabinoid solutions contain alcohol and must not be combined with these two drugs [13].

Many medicines at once, including blood thinners and heart drugs clinical data

CBD and THC are broken down by the CYP450 family of liver enzymes, which also handle many blood thinners, heart medicines, antidepressants and antipsychotics. Reviewers ask for extra caution in older adults on several medicines, because a blocked enzyme changes how fast the others are cleared [13], and for close watching of herb-drug interactions in this group [26]. The studies cited here do not name individual blood thinners, which is exactly why the full list goes to the appointment.

The safest preparation is a complete list: prescriptions with doses, over-the-counter sleep aids and allergy pills, vitamins and herbal supplements, and anything taken “only when needed.”

Questions to ask about the medicine list

  • Which of these medicines already cause drowsiness or unsteadiness, and would anything new add to that?
  • Are any of them cleared by the same liver enzymes as CBD or THC, so that their levels could rise?
  • Is there a medicine on the list that could be reduced first, before anything is added?
  • Which blood tests or checks, such as a pulse, blood pressure on standing or an ECG, make sense before and after a change?
  • Who should be told if a cannabinoid is started: the neurologist, the family doctor, the pharmacist, the care home?

Pharmacists are an underused ally here. One pharmacy filling every prescription can flag a risky pairing automatically, and many will review a full list, including supplements, on request.

What to bring to the appointment

Is Alzheimer’s a qualifying condition for a medical card?

It depends on your state, and on the exact words of its list. Each medical cannabis program publishes its own qualifying conditions, and the physician must match a diagnosis in your records to that wording. Some lists name Alzheimer’s disease outright. Others never say “Alzheimer’s” but include a condition that often comes with it, and a few let the physician certify any condition they consider debilitating.

Legislatures and health departments revise these lists, so the version in force on the day of the evaluation is the one that applies, and the physician checks it against the records during the appointment.

Listed by name

Your state names Alzheimer’s

The plainest case. A clinic note or letter recording the diagnosis is what the physician needs to evaluate under that listed condition.

Open your state’s list

Related diagnosis

A related diagnosis is listed

Insomnia, anxiety or seizures may appear where Alzheimer’s does not. It has to be diagnosed and written in the records; a symptom on its own does not count.

Check other diagnoses below

Not on the list

Neither appears

Your state may not offer a card for this yet. Some programs allow physician discretion for other serious conditions, and some accept petitions to add new ones.

Read your state’s program rules

What else has a doctor diagnosed?

State programs go by diagnosis, not symptom. Pick what is already written in the patient’s records.

Insomnia. A sleep disorder recorded alongside Alzheimer’s is common, and some programs list it. See insomnia and medical cannabis.

Anxiety. Anxiety disorders appear on several lists or fall under broader wording. See anxiety and medical cannabis.

Depression. Fewer programs list it, and THC can lift or lower mood. See depression and medical cannabis.

Pain. In later stages, pain a person cannot put into words, from arthritis, constipation or a sore tooth, often shows up as restlessness or shouting. A diagnosed pain condition in the records is one more thing for the physician to weigh.

Seizures. Seizure disorders are on many lists, and seizures occur more often in Alzheimer’s. Mind the clobazam interaction above. See seizures and medical cannabis.

None. The question then turns on how your state words its list and on the physician’s judgment. Your state’s page in the state lookup below is the place to begin.

Four things change most from one state to the next: whether the state allows medical use only or adult use as well, how much a patient may buy and hold, whether card holders skip some cannabis taxes, and whether patients may grow plants at home. Where adult-use sales are legal, anyone over the age limit can buy without a card, yet a medical card still differs in several ways.

Taxes

With a medical card

Often lower; some states drop part of the cannabis tax for patients.

Buying recreationally

The full state and local cannabis tax.

How much you can buy and hold

With a medical card

Often more, by state rule.

Buying recreationally

The adult-use limit.

Products

With a medical card

Medical dispensaries and, in some states, medical-only products.

Buying recreationally

The adult-use range.

Home cultivation

With a medical card

Allowed for patients in some states, with a plant limit.

Buying recreationally

Allowed for adults in some adult-use states, often with a lower limit.

A physician’s review

With a medical card

Diagnoses and medicines are looked at by a licensed physician.

Buying recreationally

None.

Paperwork

With a medical card

A state card or recommendation, kept in a confidential registry.

Buying recreationally

A government ID.

The exact numbers for each state, and whether Alzheimer’s is on its list today, live on that state’s page and are kept current there. The tax side is compared in medical vs recreational cannabis taxes.

Medical marijuana laws by state · How medical and recreational cannabis differ

What this means if you are considering it

Set expectations first. Cannabis might take the edge off one or two symptoms, such as evening agitation, broken sleep or a poor appetite. It will not bring memory back or change the course of the disease, and everything already prescribed stays in place. A useful evaluation focuses on one or two symptoms, the full medicine list and a clear picture of what “better” would look like.

Keep a symptom diary

With memory loss, the patient’s own account of recent weeks is the weakest evidence at the appointment. Whoever spends the most time with them can keep a short daily note on:

  • Sleep: bedtime, how many times they woke, when they got up.
  • Meals: what was eaten, and weight once a week.
  • Evenings: when restlessness or agitation started, how long it lasted, what calmed it.
  • Falls or near falls, with the time of day.
  • Any new medicine or change in dose.

What to bring to the appointment

Tap each item once it is ready. Nothing is saved.

Questions for the neurologist or geriatrician

  • Which medicines on this list could interact, and what should we watch for?
  • THC, CBD or a mix, and why that choice for this symptom?
  • What would tell us within a few weeks that it is working, or not?
  • Which signs mean stop immediately?
  • Whom do we call if confusion or sleepiness gets worse?

An evaluation makes sense if

  • One clear symptom, such as agitation, sleep or appetite, has not settled with the usual steps.
  • The whole medicine list can be reviewed.
  • Someone at home can keep doses and a log.
  • Your state’s program covers Alzheimer’s or a related diagnosis.

It is not the right step if

  • The hope is to halt or undo memory loss.
  • Confusion is new and nobody has checked why.
  • There have been several recent falls.
  • There is a past history of psychosis.

This guide summarizes published research for education and does not replace a physician’s advice. Cannabis does not treat Alzheimer’s disease or slow it in people, and older adults on several medicines face a higher risk of interactions.

How to get a medical card for Alzheimer’s online

The evaluation is an online appointment with a physician licensed in your state, done from home. With Alzheimer’s, the person who manages the medicine box is often the one who knows best what the patient takes, so have that list and the diagnosis record ready before you start. How the medical card works covers each step, from booking to registering with the state.

No diagnosis paperwork at hand? Ask the clinic that made the diagnosis for a visit note, or download it from the patient portal you already use with that clinic. Without a record, the physician may not be able to confirm a qualifying condition.

If the physician recommends cannabis, the signed document appears in your account. Many state programs also let a registered caregiver buy at a dispensary for the patient, which matters once shopping alone is no longer safe.

Who runs the appointment

4.6out of 5 on Google

Across 250 reviews from patients in the states where we are licensed. We do not sort them by score and do not hide the low ones.

  • 150,000+patients evaluated – everyone who has been through an appointment with us, in every state where we are licensed
  • Since 2017doing only this: online evaluations for medical cannabis programs, and nothing else on the side

The physicians are listed by name on our doctors page, and what’s included in the price shows what the fee covers.

Renewing the card as the disease progresses

Cards expire on a schedule each state sets, and renewal means a fresh evaluation. With Alzheimer’s that is useful rather than a formality: symptoms, weight and medicines shift over a year, and the physician should hear what changed. If agitation, sleep or swallowing changes sharply before the renewal date, book a review instead of waiting. As the illness moves on, the family often takes over the paperwork, so keep the renewal date somewhere more than one person can see it.

Renewing

Book a repeat evaluation before the card expires and bring an updated medicine list and any new diagnoses. In registry states the state card is renewed as well, and a registered helper, where the state has one, follows the same program rules. Renewal pages by state are in the state lookup, and the medical card FAQ covers the common questions.

If the card is lost

Ask the state program that issued it for a replacement; most handle this in the portal you registered through. Steps for a lost medical card walks through it.

What to note between evaluations

A renewal visit is only as useful as what the physician hears. A page in the care notebook, filled in once a month, turns a vague “about the same” into something a doctor can act on.

  • Sleep: hours at night, naps, and how often the person wakes.
  • Behavior: evenings, agitation, suspicion or hallucinations, and what seemed to set them off.
  • Eating and weight: the weekly weight, coughing at meals, any trouble swallowing.
  • Falls and near falls, with the time of day.
  • Every medicine change made by any doctor since the last visit, and every product and dose given.
  • Who now manages the paperwork, and whether a helper or a care facility needs to be added or updated.

What’s included in the price, and what if no recommendation is issued

Two fees can be involved, and they go to different places. The table shows who receives each one and when you see it.

What you pay for a medical card evaluation
FeePaid toWhen you see it
Evaluation feeDr. Weedy, for the review of your history and the appointment with a licensed physicianOn screen before you pay; nothing is added afterward
State registration feeThe state program, not usSet by the state, only where it runs a registry
Reduced-cost optionsPrograms for veterans and for people on a low incomeCheck the page before you start

Whether to issue a recommendation is the physician’s medical decision, made at the appointment, and it is never promised in advance. What happens to the fee in that case is explained in the medical card FAQ, so you can read it before paying.

Who wrote and reviewed this page

The Dr. Weedy editorial team wrote this guide and the Dr. Weedy medical team checked it. Studies on Alzheimer’s are labeled by type throughout, so results from mice or cell dishes never stand in for results in patients. If something here is out of date, tell the editors.

Questions people ask about Alzheimer’s and medical cannabis

Can Alzheimer’s kill you, and what is the life expectancy?

Yes, Alzheimer’s shortens life, mostly through what happens in the late stage: swallowing problems lead to pneumonia, and being bedbound leads to infections and pressure sores. How long someone lives after diagnosis depends heavily on age and other illnesses, and many people live for years. Cannabis has not been shown to change that course.

Can Alzheimer’s get better or go away on its own?

No, the disease keeps progressing. Someone can have clearer weeks once an infection clears, a medicine is changed or sleep settles, which is exactly why a sudden turn for the worse always deserves a check.

What is Alzheimer’s lucidity?

Families sometimes describe a short spell, minutes or a day, when a person in a late stage suddenly recognizes them, speaks clearly or recalls old details. Doctors call it paradoxical or terminal lucidity. It is not a sign that the disease is lifting, and nobody can predict it. Many families simply use the moment to talk.

Does Alzheimer’s make you sleep more?

Often in the later stages, when people may sleep through much of the day and wake at night. A sudden change in sleep is still worth checking against new medicines, infections and pain. Sleepiness from THC can look like calmer days while nights stay broken.

Why does Alzheimer’s sometimes not start with forgetfulness?

Memory is the classic first sign, yet families often notice something else first: a personality change, odd decisions about money, getting lost while driving, or hunting for words. Rarer forms of Alzheimer’s begin with vision, language or planning problems instead of memory.

Are hallucinations part of Alzheimer’s?

They can be, usually in the middle and late stages: seeing people or animals that are not there. New hallucinations should also be checked for infection, failing eyesight or a medicine side effect. THC can cause or worsen hallucinations and paranoia, so mention them before any cannabis product is considered.

Alzheimer’s vs other dementias: is one worse?

Not in a simple way. Alzheimer’s is the most common cause of dementia; others include vascular dementia, Lewy body dementia and frontotemporal dementia, each with its own pattern. Lewy body dementia, for example, brings hallucinations early and a strong sensitivity to antipsychotics. The comparison table sets them side by side.

Is CBD or THC better for agitation in dementia?

Nobody knows yet. The agitation trials mostly used THC, as dronabinol or in combination products, and their results were mixed [12]. CBD on its own has hardly been tested in patients. Each comes with its own trade-off: THC brings sleepiness and paranoia, CBD changes the levels of other drugs. The choice is one for the physician who sees the medicine list.

Is CBD alone safe with dementia medicines?

Not automatically. CBD does not cause a high, but it slows liver enzymes that clear many drugs; with clobazam it multiplied the active drug four- to five-fold [13]. No study cited here tested CBD with donepezil or memantine directly. Bring the actual CBD product and the full list to the appointment.

What about delta-8 THC or CBD products sold without a card?

Hemp-derived products sold in stores and online are usually less tightly regulated than dispensary products, and the label may not match the contents. Delta-8 THC acts much like ordinary THC, with the same drowsiness, confusion and interaction risks. Reviewers advise against unregulated products in Alzheimer’s care [15].

Can medical cannabis be used in a nursing home or memory care?

Each facility decides, within its state’s law. Many have a written policy, and some do not allow cannabis on the premises even with a card. Ask for the policy in writing before bringing anything in, and give the nursing staff the complete medicine list so they can watch for sleepiness and falls. More in attendance and consent.

Can I use my card in another state?

Sometimes. Reciprocity, one state honoring another’s card, exists in some places and not in others, and visitor rules vary. Before a trip, check which states accept out-of-state cards and read about traveling with cannabis.

What if my card is lost?

Contact the state program that issued it; replacements usually go through the portal used for registration. The full steps are in what to do about a lost card.

How do I renew my medical card?

Before it expires, book a repeat evaluation and bring an updated medicine list and any new diagnoses. The physician issues a new recommendation if it is still appropriate, and in registry states you renew the state card as well. Your state’s renewal page is in the state lookup, and the medical card FAQ has the details.

How much does it cost, and what if I’m not approved?

The price of the evaluation in your state appears before payment, and state program fees are separate. Approval is never promised: the physician makes a medical decision at the appointment. What happens in that case is explained in the medical card FAQ; the fees are broken down in what’s included in the price.

Is an online evaluation legitimate?

Yes, in states whose law allows telemedicine for medical cannabis evaluations. The physician holds a license in your state, sees the patient one-on-one, and signs the same recommendation an office visit would produce.

Who finds out? Privacy, firearms and work

Medical records from the evaluation fall under the HIPAA Privacy Rule [35], and state registries are confidential. Federal law still bars unlawful users of controlled substances from owning guns [34], and employment protections depend on the state. The driving, firearms, work and privacy section goes through each.

What is the ICD-10 code for Alzheimer’s?

G30, split into G30.0 (early onset), G30.1 (late onset), G30.8 (other) and G30.9 (unspecified). The code on a visit note can help the physician confirm the diagnosis.

How can Alzheimer’s be prevented?

No proven method exists. Good blood pressure and blood sugar control, treating hearing loss, staying active and keeping company are linked to lower dementia risk overall. Cannabis has not been shown to prevent Alzheimer’s.

More medical card questions · Health and wellness articles

More research on cannabis and Alzheimer’s disease

This page cites a selection of studies. Our research library holds every study we track on cannabis and Alzheimer’s disease, from laboratory work to clinical trials, and lets you filter them by cannabinoid, study type and year.

studies
1,600+
in people
500+
clinical trials
96

See the studies on Alzheimer’s disease

Alzheimer’s rarely comes alone. These five conditions are linked to it through shared symptoms or a shared brain process, and each page covers its own research and state rules.

Alzheimer’s resources, support groups and latest research

For day-to-day help, the Alzheimer’s Association keeps a round-the-clock helpline and a directory of local support groups [11], and the National Institute on Aging publishes free guides on diagnosis, care and clinical trials [2]. To find a memory center or a support group near you, ask a primary care doctor for a referral or check the neurology department of the nearest university hospital. The newest work cited on this page dates from 2026, including the brain-tissue study of CB1 receptors [3] and the largest genetic analysis so far [4]; every study we track on the topic is in our research library.

Background reading

Talk to a licensed physician about Alzheimer’s symptoms

What cannabis may do: take the edge off agitation, broken nights or a poor appetite for some people, under a physician’s eye.

What it cannot do: treat Alzheimer’s, slow it, or replace what is already prescribed.

You see the fee for your state before paying. Whether cannabis is recommended is the physician’s call at the appointment.

Share your experience

Leave an anonymous messageTell us what this page failed to answer, or where we got something wrong. It goes to the team, not onto the page, and no account or email is needed.
Share your storyA longer account of living with this condition, written for the people who arrive at this page next. Published with your first name, or anonymously if you ask.
Write a public commentAsk a question, correct us, or answer somebody else’s question at the foot of this page. Comments are public once they clear moderation.Add a comment

    💬

    How else can we help you?

    Tell us what you’d like to see, learn, or get from us next.

    🕶️
    100% anonymous — share what’s on your mind
    We will only use it if we need to follow up on your message.

      💬

      Share Your Story with the Dr. Weedy Community

      Your positive, negative, or neutral experience can really help others. Feel free to share it in a few clear, short sentences.

      🕶️
      Your contact details are encrypted and will never be shared publicly

      References

      35 sources
      1. 1. Rajji TK, Baksh SN, Shade DM, et al. Escitalopram for agitation in Alzheimer’s dementia: a randomized controlled phase 3 trial. Nat Med · 2025 · rct DOI: 10.1038/s41591-025-03569-y PMID: 40133524
      2. 2. National Institute on Aging. Alzheimer’s Disease Fact Sheet. 2023.
      3. 3. von Borcke N, Purwien AV, Steiert A, et al. Reduced CB1 Cannabinoid Receptor Expression in Alzheimer’s Disease and Transgenic Mouse Models. Aging Med (Milton) · 2026 · case_control DOI: 10.1002/agm2.70080 PMID: 42130756
      4. 4. EADB, EADI, Bonn, et al. Consensus meta-analysis of genome-wide association studies for Alzheimer’s disease and related dementias. Nat Genet · 2026 · meta_analysis DOI: 10.1038/s41588-026-02583-1 PMID: 42237039
      5. 5. ADGC, Bonn, CHARGE, EADB, EADI, FinnGen, GERAD, GR@ACE/DEGESCO, PGC-ALZ Consensus meta-analysis of genome-wide association studies for Alzheimer’s disease and related dementia. medRxiv · 2025 · meta_analysis DOI: 10.1101/2025.10.20.25338060 PMID: 41282675
      6. 6. Vered S, Beiser AS, Sulimani L, et al. Circulating Endocannabinoids and Cognitive Function in Older Adults. Aging Dis · 2024 · cross_sectional DOI: 10.14336/AD.2024.1427 PMID: 39812547
      7. 7. Fink HA, Sheets KM, Langsetmo L, et al. Effects of Functional Impairments and Frailty on the Association of Cognitive Impairment with Total Healthcare Costs: A Prospective Multi-cohort Study. J Gen Intern Med · 2025 · cohort DOI: 10.1007/s11606-025-10073-z PMID: 41366620
      8. 8. Corbett A, Sultana J, Stych K, et al. Drug repurposing for Alzheimer’s disease: a Delphi consensus and stakeholder consultation. Alzheimers Res Ther · 2025 · narrative_review DOI: 10.1186/s13195-025-01895-4 PMID: 41250235
      9. 9. U.S. Food and Drug Administration. FDA and Cannabis: Research and Drug Approval Process. 2023.
      10. 10. Jagasia K, Malyan HH, Kim J, et al. Cannabis Use Among Caregivers of Older Adults: A Systematic Literature Review. Sage Open Aging · 2026 · narrative_review DOI: 10.1177/30495334261426511 PMID: 41767904
      11. 11. Alzheimer’s Association. 24/7 Helpline. 2026.
      12. 12. Komedera M, Wojda U, Kiryk A Cannabinoids in Alzheimer’s disease: animal-human evidence and clinical pharmacology challenges. Front Behav Neurosci · 2026 · narrative_review DOI: 10.3389/fnbeh.2026.1833021 PMID: 42211879
      13. 13. Tudorancea IM, Filipiuc LE, Vieru DS, et al. Navigating dose-effect complexities and challenges in cannabinoid therapy for aging-related neurobiological changes. Front Pharmacol · 2026 · narrative_review DOI: 10.3389/fphar.2026.1794928 PMID: 42292844
      14. 14. Watt G, Olaya J, Muench G, et al. Effects of Chronic 100 mg/kg Cannabidiol Treatment in Male Double Transgenic APPSwe/PS1∆E9 Mice. Pharmaceuticals (Basel) · 2026 · preclinical DOI: 10.3390/ph19030374 PMID: 41901221
      15. 15. Dos Santos Silva J Cannabinoids for Alzheimer’s disease: A promising trial, although not yet ready for the prescription pad. J Alzheimers Dis · 2026 · rct DOI: 10.1177/13872877261452183 PMID: 42216668
      16. 16. Oddi S, Scipioni L, Totaro A, et al. Fatty-acid amide hydrolase inhibition mitigates Alzheimer’s disease progression in mouse models of amyloidosis. FEBS J · 2025 · preclinical DOI: 10.1111/febs.17403 PMID: 39822137
      17. 17. Sznitman SR, Vered S, Weinstein G History of cannabis use and cognitive function in older adults: findings from the UK biobank. Age Aging · 2025 · cohort DOI: 10.1093/aging/afaf319 PMID: 41189327
      18. 18. Yao YY, Maxwell CJ, Ismail Z, et al. Cannabis Use Prevalence and Correlates in Patients Attending a Canadian Cognitive Clinic. Can J Neurol Sci · 2025 · cross_sectional DOI: 10.1017/cjn.2025.64 PMID: 40207445
      19. 19. Liu J, Peng F, Li P, et al. Mechanistic insights into cannabidiol-mediated TrkB activation via FRS2 interaction in attenuating Alzheimer’s disease pathology and cognitive impairment. Mol Psychiatry · 2026 · preclinical DOI: 10.1038/s41380-026-03525-3 PMID: 41857397
      20. 20. Specka M, Rabl J, Bonnet U, et al. Attitudes of Patients with Non-Psychotic Mental Disorders Towards Cannabis After Its Legalization-Comparison with Patients Before Legalization. Brain Sci · 2026 · cross_sectional DOI: 10.3390/brainsci16070730 PMID: 42512504
      21. 21. Grill JD, Raman R, Flournoy C, et al. Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trial. Alzheimers Dement · 2025 · cohort DOI: 10.1002/alz.14623 PMID: 39988989
      22. 22. Zheng X, Worhunsky P, Liu Q, et al. Generating synthetic brain PET images of synaptic density based on MR T1 images using deep learning. EJNMMI Phys · 2025 · cohort DOI: 10.1186/s40658-025-00744-5 PMID: 40163154
      23. 23. Akinyemi E, Randhawa G, Longoria V, et al. Medical Marijuana Effects in Movement Disorders, Focus on Huntington Disease; A Literature Review. J Pharm Pharm Sci · 2020 · systematic_review DOI: 10.18433/jpps30967 PMID: 33064979
      24. 24. Hoch E, Niemann D, von Keller R, et al. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci · 2019 · systematic_review DOI: 10.1007/s00406-019-00984-4 PMID: 30706168
      25. 25. Wilkinson ST, Radhakrishnan R, D’Souza DC A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. J Clin Psychiatry · 2016 · systematic_review DOI: 10.4088/JCP.15r10036 PMID: 27561138
      26. 26. Siam NH, Nasrin N, Saiyara S, et al. Medicinal Plants and Their Bioactive Phytochemicals as Emerging Therapeutic Strategies for Alzheimer’s Disease: An Integrative Review of Preclinical and Clinical Evidence. Scientifica (Cairo) · 2026 · narrative_review DOI: 10.1155/sci5/6124916 PMID: 42382677
      27. 27. Kumari A, Zeng XA Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. Nutrients · 2026 · narrative_review DOI: 10.3390/nu18060907 PMID: 41901082
      28. 28. Dagla I, Gkikas F, Gikas E, et al. Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s Disease: Advances and Future Directions. Cells · 2026 · narrative_review DOI: 10.3390/cells15030295 PMID: 41677657
      29. 29. Rajabli F, Benchek P, Tosto G, et al. Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies known and novel cross-population and ancestry-specific associations as novel risk loci for Alzheimer’s disease. Genome Biol · 2025 · meta_analysis DOI: 10.1186/s13059-025-03564-z PMID: 40676597
      30. 30. Balbona JV, Jeffries P, Gorelik AJ, et al. Leveraging Genomic Data to Examine the Causal Impact of Alcohol, Tobacco, Cannabis, and Opioid Use on Biological and Cognitive Aging. Addict Biol · 2025 · cohort DOI: 10.1111/adb.70066 PMID: 40653731
      31. 31. Kong Y, Lv X, Yang Y, et al. Lactobacillus mucosae Reduces Neuronal Oxidative Stress in Alzheimer’s Disease via the Regulation of CB2 Signaling. J Integr Neurosci · 2026 · preclinical DOI: 10.31083/JIN48598 PMID: 42216640
      32. 32. Salama A, Elgohary R, Elesawy WH Valsartan Mitigates LPS-Induced Neuroinflammation and Cognitive Deficits via Modulation of RAS-ECS Crosstalk in Mice. Mol Neurobiol · 2026 · preclinical DOI: 10.1007/s12035-026-05728-9 PMID: 41820755
      33. 33. Zhang H, Li Z, Xiao Y, et al. Gut Microbiota-Derived Anandamide Mediates the Therapeutic Effects of Urolithin A on Alcohol-Induced Cognitive and Social Dysfunction via CB1R-DRD2-RAP1 Signaling Axis. Adv Sci (Weinh) · 2026 · preclinical DOI: 10.1002/advs.202508048 PMID: 41632030
      34. 34. Legal Information Institute, Cornell Law School. 18 U.S. Code § 922: Unlawful acts. 2024.
      35. 35. U.S. Department of Health and Human Services. The HIPAA Privacy Rule. 2024.
      0 Comments
      Security check required

      Our security system needs to verify your connection. Please reload the page and complete the quick verification — your details are safe and nothing was lost.